Demand for COVID-tests (account for nearly 50% of its total revenue) will continue with the lower vaccination rate in its operating countries and increasing incoming foreign tourists.
Increasing contribution from high-value house calls, walk-in patients, and radiology services should act as margin drivers for the company, amid recovery of conventional test revenue at IDH.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.